JP2021518104A5 - - Google Patents

Info

Publication number
JP2021518104A5
JP2021518104A5 JP2020548722A JP2020548722A JP2021518104A5 JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5 JP 2020548722 A JP2020548722 A JP 2020548722A JP 2020548722 A JP2020548722 A JP 2020548722A JP 2021518104 A5 JP2021518104 A5 JP 2021518104A5
Authority
JP
Japan
Prior art keywords
sequence
seq
region
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020548722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518104A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022272 external-priority patent/WO2019178356A1/en
Publication of JP2021518104A publication Critical patent/JP2021518104A/ja
Publication of JP2021518104A5 publication Critical patent/JP2021518104A5/ja
Priority to JP2024018466A priority Critical patent/JP2024054286A/ja
Withdrawn legal-status Critical Current

Links

JP2020548722A 2018-03-14 2019-03-14 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 Withdrawn JP2021518104A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024018466A JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643040P 2018-03-14 2018-03-14
US62/643,040 2018-03-14
US201862657151P 2018-04-13 2018-04-13
US62/657,151 2018-04-13
PCT/US2019/022272 WO2019178356A1 (en) 2018-03-14 2019-03-14 Engineered cells, t cell immune modulating antibodies and methods for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018466A Division JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2021518104A JP2021518104A (ja) 2021-08-02
JP2021518104A5 true JP2021518104A5 (https=) 2022-04-05

Family

ID=67908100

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020548722A Withdrawn JP2021518104A (ja) 2018-03-14 2019-03-14 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024018466A Pending JP2024054286A (ja) 2018-03-14 2024-02-09 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法

Country Status (5)

Country Link
US (2) US12258378B2 (https=)
EP (1) EP3765070A4 (https=)
JP (2) JP2021518104A (https=)
AU (2) AU2019235900B2 (https=)
WO (1) WO2019178356A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119644A1 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
EP3983447A4 (en) 2019-06-14 2023-06-28 Dana-Farber Cancer Institute, Inc. Antibodies against muc1 and methods of use thereof
EP4069294A4 (en) * 2019-12-02 2024-07-10 Dana-Farber Cancer Institute, Inc. Antibodies against pd-l1 and methods of use thereof
WO2021164959A1 (en) * 2020-02-17 2021-08-26 Miltenyi Biotec B.V. & Co. KG Method for providing personalized cells with chimeric antigen receptors (car) against tumor microenvironment cells
AU2022262542A1 (en) * 2021-04-22 2023-11-02 Astellas Pharma Inc. Anti-cldn4/anti-cd137 bispecific antibody
TW202342737A (zh) * 2022-02-07 2023-11-01 中國大陸商杭州啟函生物科技有限公司 增強免疫療法的系統和方法
CN114686592B (zh) * 2022-05-30 2022-09-09 广东忠信生物科技有限公司 一种多类型靶标联合检测的试剂盒及制备方法、使用方法
EP4572785A1 (en) 2022-08-15 2025-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
CN118252937B (zh) * 2024-04-07 2024-10-22 中山大学 Cxcr4受体的拮抗剂在抗埃博拉病毒感染中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2005060520A2 (en) 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
US8466263B2 (en) 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
RU2010127156A (ru) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) Антитела против вируса гриппа и их применение
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009134962A2 (en) 2008-04-30 2009-11-05 The Regents Of The University Of California Claudin-4 binding peptides, compositions and methods of use
AU2011261396B2 (en) 2010-06-02 2015-11-05 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP3511343A1 (en) 2012-05-04 2019-07-17 Dana Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
MX367668B (es) 2013-03-15 2019-08-30 Dana Farber Cancer Inst Inc Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos.
EP4043489A1 (en) 2014-03-19 2022-08-17 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
KR20160145813A (ko) 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
TWI751102B (zh) * 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
EA201790489A1 (ru) * 2014-08-29 2017-08-31 Сорренто Терапьютикс, Инк. ТЕРАПЕВТИЧЕСКИЕ СРЕДСТВА НА ОСНОВЕ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ OprF И OprI
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
EP3204418B1 (en) 2014-10-06 2020-03-25 Dana Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
EP3029067A1 (en) * 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
EP3233900A2 (en) * 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
KR102668588B1 (ko) 2015-04-08 2024-05-22 다나-파버 캔서 인스티튜트 인크. 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법
JO3620B1 (ar) * 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
EP3349792A1 (en) * 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-

Similar Documents

Publication Publication Date Title
JP2021518104A5 (https=)
Lu et al. Development of therapeutic antibodies for the treatment of diseases
JP2022512653A5 (https=)
JP2024054286A5 (https=)
JP2022512684A5 (https=)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US11578133B2 (en) Antibodies targeting CD137 and methods of use thereof
JP2022513668A5 (https=)
JP2018533371A5 (https=)
JP2022512917A5 (https=)
KR20190028716A (ko) Pd-l1-특이적 항체 및 이를 사용하는 방법
KR20160024391A (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
JP2011509245A5 (https=)
JP2022533538A5 (https=)
IL295381A (en) bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
JP2022544825A5 (https=)
JP2022514734A5 (https=)
JP2023519099A5 (https=)
WO2021186056A1 (en) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2021013142A1 (zh) 抗4-1bb抗体、其抗原结合片段及双特异性抗体
JP7418326B2 (ja) 二重特異性抗体並びにその製造方法及び使用方法
JP2025530888A5 (https=)
CN116178545B (zh) 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用
JPWO2022044573A5 (https=)
JP2024541476A5 (https=)